Abstract | INTRODUCTION: AREA COVERED: EXPERT OPINION: In patients with inadequate responses to bDMARDs and JAK inhibitors, switching between these drugs is comparable in efficacy in both directions. Head-to-head comparison demonstrated that baricitinib and upadacitinib are more efficacious than tumor necrosis factor ( TNF) inhibitors. However, the ORAL Surveillance study demonstrated that JAK inhibitors are associated with higher incidences of death, major adverse cardiovascular events, malignancies and thrombosis than TNF inhibitors in at-risk patients. The need for risk assessment by pre-treatment screening, regular monitoring during treatment, and appropriate systemic management in adverse events should be recognized. Meanwhile, some JAK-inhibitors were efficacious even for difficult-to-treat disease. These results suggest the need for establishing therapeutic strategies considering the balance between safety and efficacy in individual patients.
|
Authors | Yoshiya Tanaka |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
2023 Sep-Dec
Vol. 24
Issue 16
Pg. 1791-1798
ISSN: 1744-7666 [Electronic] England |
PMID | 37563102
(Publication Type: Journal Article, Review)
|
Chemical References |
- Janus Kinase Inhibitors
- Antirheumatic Agents
- Tumor Necrosis Factor Inhibitors
- Biological Products
|
Topics |
- Humans
- Janus Kinase Inhibitors
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Antirheumatic Agents
(adverse effects)
- Tumor Necrosis Factor Inhibitors
(therapeutic use)
- Biological Products
(adverse effects)
|